Case Series of Mucormycosis in Post COVID 19 Patients with Hematological Malignancies in Ongoing Pandemic

Article Sidebar

PDF
Published: Feb 23, 2022
DOI: https://doi.org/10.47191/ijmscrs/v2-i2-11
Keywords:
mucorrnycosis, antifungals, endoscopic surgery, haematological malignancy, COVID 1

Main Article Content

Dr. S B Amarnath MS(ENT)
Associate Professor, Incharge Head of Department, Department of Otorhinolaryngology, SVIMS and Sri Padamavati medical college,Tirupati, Andhra Pradesh- 517507
Dr. Prerana Anthwal MS(ENT)
2Assistant Professor, Department of Otorhinolaryngology, SVIMS and Sri Padamavati medical college, Tirupati, Andhra Pradesh- 517507
Dr. SivaKumar Vulava MD(Pathology)
Assistant Professor, Department of Pathology, SVIMS and Sri Padamavati medical college, Tirupati, Andhra Pradesh- 517507
Dr. Bodagala Vijaylakshmi Devi MD (Radiology)
Professor & Head of Department of Radiology, SVIMS and Sri Padamavati medical college,Tirupati, Andhra Pradesh- 517507

Abstract

Rhinocerebral mucormycosis is a lethal infection caused by saprophytic fungi in immunocompromised patients. Haematological malignancy patients with superseeded COVID 19 infection are more predisposed to mucormycosis with high mortality.

Article Details

How to Cite
MS(ENT), D. S. B. A., MS(ENT), D. P. A., MD(Pathology), D. S. V., & MD (Radiology), D. B. V. D. (2022). Case Series of Mucormycosis in Post COVID 19 Patients with Hematological Malignancies in Ongoing Pandemic. International Journal of Medical Science and Clinical Research Studies, 2(2), 138–146. https://doi.org/10.47191/ijmscrs/v2-i2-11
Issue
Vol. 2 No. 2 (2022): Volume 02 Issue 02 February 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Bouza E, Muñoz P, J Guinea J. Mucormycosis: an emerging disease? Clinical

Microbiology and Infection 2006; 12(Suppl7): 7-23.

II. Brown SR, Shah IA, Grinstead M. Rhinocerebral mucormycosis caused by Apophysomyces elegans. Am J Rhinol. 1998 Jul-Aug;12(4):289-92.

III. Yohai RA, Bullock JD, Aziz AA, et al. Survival factors in rhino-orbital-cerebral mucormycosis: major review. Surv Ophthalmol1994;39:3–22.

IV. Ferry AP, Abedi S. Diagnosis and management of rhino-orbitocerebralmucormycosis (phycomycosis): a report of 16 personally observed cases. Ophthalmology1983;90:1096–104

V. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30:851–856

VI. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–917.

VII. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13:236–301.

VIII. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–653.

IX. Gandhi BV, Bahadur MM, Dodeja H, Aggrwal V, Thamba A, Mali M. Systemic fungal infections in renal diseases. J Postgrad Med. 2005;51(Suppl 1):S30–S36.

X. Almyroudis N.G., Sutton D.A., Linden P., Rinaldi M.G., Fung J., Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am. J. Transplant. 2006;6:2365–2374. doi: 10.1111/j.1600-6143.2006.01496.

XI. Anand VK, Alemar G, Griswold JA. Intracranial complications of mucormycosis: an experimental model and clinical review. Laryngoscope. 1992 Jun;102(6):656-62.

XII. Petrikkos G, Skiada A,Lortholary O,Rolilides E, Walsh TJ,Kontonyiannis DP:Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 54 Suppl 1:S23-34,2012

XIII. Noorifard M, Sekhavati E, Jalaei Khoo H, Hazraty I, Tabrizi R. Epidemiology and clinical manifestation of fungal infection related to Mucormycosis in hematologic malignancies. J Med Life. 2015;8(Spec Iss 2):32-3

XIV. S Sarvestani A, Pishdad G, Bolandparvaz S. Epidemiology and Clinical Characteristics of Mucormycosis in Patients with Leukemia; A 21-year Experience from Southern Iran. Bull Emerg Trauma. 2014 Jan;2(1):38-43.

XV. Paltauf A. Mycosis mucorina. Arch Pathol Anat. 1885;102:543–64.

XVI. .Baker R.D. Mucormycosis-a new disease? J Am Med Assoc. 1957;163:805–808.

XVII. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based

frontline therapy significantly increases mortality among patients with

hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503

XVIII. Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment

Options, Laryngoscope, 1997, vol. 107

(pg. 855-862)

XIX. Talmi YP, Goldschmied-Reouven A, BakonM, et al. Rhino-orbital and rhino-orbitocerebral mucormycosis, Otolaryngol Head Neck Surg, 2002, vol. 127 (pg. 22-31)

XX. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41(5):634-53.